List view / Grid view
BenevolentAI, a British artificial intelligence company, has partnered with MRC Technology (MRCT), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.
Draper's Joe Charest explains how synthetic organoids can lead to safer drug testing, and why organ-on-a-chip technology is the future of drug discovery...
Mundipharma EDO GmbH's Dr Thomas Mehrling talks through the benefits of streamlining the drug discovery and development process using the EDO model...
Neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease are a global health, economic and social emergency.
The outlook for brain tumour patients is pretty negative, with the median survival rate for patients with glioblastoma multiforme, or GBM, a mere 14.2 months.
21 July 2015 | By Victoria White
University of Queensland researchers have discovered thousands of new peptide toxins hidden deep within the venom of just one type of cone snail...
15 October 2014 | By Domainex
Domainex Ltd. and Auspherix Pty Ltd announced a collaboration that will progress Auspherix’s novel anti-infective drug discovery programme towards the nomination of a clinical candidate...
